This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (16)  • Contact me when this article is cited  Related Content  • Similar articles in this journal

Arch Ophthalmol. 2000;118:577-578.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Retinoblastoma is the most common intraocular tumor in children.¹ Historically, the treatment of retinoblastoma was enucleation.¹ However, improvements in diagnosis and treatment of retinoblastoma have led not only to a survival rate well over 90%,¹ but also to an increasing ability to offer globe conservation as a secondary goal of therapy. Globe-conserving therapies include cryotherapy, laser photoablation, hyperthermia, and plaque radiotherapy for smaller tumors, and external beam radiation and systemic chemotherapy for larger tumors not amenable to local control.²

Recently, multiple-agent chemotherapy with etoposide phosphate, carboplatin, and vincristine sulfate combined with transpupillary hyperthermia has been demonstrated to achieve excellent local control of retinoblastoma.³ Further, systemic chemotherapy spares the patient the risk of craniofacial abnormalities and may eliminate or decrease the risk of secondary tumors that have been associated with external beam radiation.⁴ However, systemic chemotherapy employed for retinoblastoma has been associated with adverse events such as myelosuppression and subsequent infections . . . [Full Text of this Article]

Report of Cases


Comment
Matthew S. Benz, MD; Ingrid U. Scott, MD, MPH; Timothy G. Murray, MD; Deborah Kramer, MD; Stuart Toledano, MD
Miami, Fla

Corresponding author: Timothy G. Murray, MD, Bascom Palmer Eye Institute, 900 NW 17th St, Miami, FL 33136 (e-mail: tmurray@bpei.med.miami.edu).

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Targeting Hypoxia, a Novel Treatment for Advanced Retinoblastoma
Boutrid et al.
IOVS 2008;49:2799-2805.
ABSTRACT | FULL TEXT  

Inhibitory Effect of Bevacizumab on the Angiogenesis and Growth of Retinoblastoma
Lee et al.
Arch Ophthalmol 2008;126:953-958.
ABSTRACT | FULL TEXT  

The Adverse Events of Chemotherapy for Retinoblastoma: What Are They? Do We Know?
Rizzuti et al.
Arch Ophthalmol 2008;126:862-865.
FULL TEXT  

Paclitaxel in the Treatment of Retinal Tumors of LH beta-Tag Murine Transgenic Model of Retinoblastoma
Suarez et al.
IOVS 2007;48:3437-3440.
ABSTRACT | FULL TEXT  

Iontophoretic delivery of Carboplatin in a murine model of retinoblastoma.
Hayden et al.
IOVS 2006;47:3717-3721.
ABSTRACT | FULL TEXT  

Anecortave Acetate as Single and Adjuvant Therapy in the Treatment of Retinal Tumors of LHBETATAG Mice.
Jockovich et al.
IOVS 2006;47:1264-1268.
ABSTRACT | FULL TEXT  

Effects of celecoxib in human retinoblastoma cell lines and in a transgenic murine model of retinoblastoma
Tong et al.
Br. J. Ophthalmol. 2005;89:1217-1220.
ABSTRACT | FULL TEXT  

Combretastatin A-4 Prodrug in the Treatment of a Murine Model of Retinoblastoma
Escalona-Benz et al.
IOVS 2005;46:8-11.
ABSTRACT | FULL TEXT  

External Beam Radiation "Salvage" Therapy in Transgenic Murine Retinoblastoma
Sobrin et al.
Arch Ophthalmol 2004;122:251-257.
ABSTRACT | FULL TEXT  

Comparison of Retinoblastoma Reduction for Chemotherapy vs External Beam Radiotherapy
Sussman et al.
Arch Ophthalmol 2003;121:979-984.
ABSTRACT | FULL TEXT